I figured as much. At first glance the new Perjeta numbers looked impressive, but when you look at the Roche presentation info referenced below, it's clear to me that Roche is expecting the final best combo to be Perjeta and Kadcyla. The issue with that combo will be cost, assuming Kad adds to both safety and efficacy vs. Herceptin and not just PFS, but OS. The next issue to settle is which is better alone, P or K, or is there a bio-marker to predict in which patients one will will work better than the other. I am sure Roche is figuring this all out for patients and for their bottom line.
thanks, yes I decided to stop being lazy and read the article, very interesting. One day they will arrest him and some of his hedge fund partners in crime IMO.
did the article name AF and provide any facts? I have seen this mentioned on other boards. Short criminals are all over this industry, would love to see them exposed and prosecuted finally.
it's not going to $18 again, it's either going up big if/after acquisition, flat to up after approval, or down big if something bad happens. Hoping an acquisition removes the risk and any decision-making.
When retail investors start bragging about how much they made in a stock it's a reliable sell signal and magnet to short sellers. Unless/until either the company is acquired, or Pima is approved and the stock goes up, or you sell, I would not start celebrating.
The future for Her+ patients is Kad + Perj. Kad is clearly more safe and effective than Herceptin. There's no study adding both Herceptin and Kad with Perj, that would be toxic and redundant.
Thanks for your contributions CH. I think ARNA is starting to turn the corner, you might want to keep an eye on them. Only problem is similar to IMGN, weak CEO.
I think you posters have overly high expectations. If insiders are selling stock in the $20's do you really think the company is worth $50, 75, $100 right now? If they get an offer soon it's likely to be under $50. If they show efficacy in Alzheimer's, then the price will sky rocket, but that's at least 1-2 years out. Prior to PDP approval and a successful launch, the current stock price is pretty fair/fully valued. Maybe we get up to $30 before an offer or approval, but not much higher until a successful launch is verified. IMO of course.
Good relative and good to grow off the large number last week, but I was hoping for more considering the extra advertising and Bel-Phen info...
most of their long holdings in biotech are also heavily shorted. I would think they would have to list that (shorts against longs) as a sale for tax and reporting purposes. Maybe they "invest" in another firm that does the shorting to avoid this?
Some good activity in the Oct calls and a large spread in the Jan calls, probably a buy of the 25 and sell of the 30. Someone keeps trying to time a negative, unexpected announcement buying the near term puts.
sure and the GNTA former CEO told everyone that Genasense would be used for every type of cancer and with every type of therapy. They are out of business now. Most/many Biotech CEO's are little more than cheerleaders and the market ignores them. Clearly the market is only reacting to what JL does (sell stock) and not what he says (excited or very excited). The market players want him OUT ASAP.
That said, it looks like a little base has formed, maybe another run soon although the performance today is quite SAD.
excellent idea, let's get on this bashers, it will pay much better than .01/post or response, or whatever you earn.
can someone translate this into English for business people. What does it do/cure, how is it beneficial/better that what is currently available, what's the potantial market size, has it been tested in humans, will something useful and profitable be developed in our investment lifetime...
Part of an article from FierceBiotech is below. They are paying a lot for a technology that would seem to be inferior to ADC's. ...paying $100 million in an upfront fee and committing up to $870 million in additional milestones for the late-stage treatment.
Baxter, which is reportedly considering a move to Boston after spinning out its biopharma division under the name Baxalta, is adding MM-398 to its drug portfolio. The experimental therapy is made up of the chemo drug irinotecan wrapped in a nanoliposomal capsule to provide extended circulation in patients, amping up its effect on cancer. And while it failed to provide a significant improvement in survival rates as solo therapy, it did hit the goal line in a combination approach to a very tough type of cancer.
yes, that's why I mention it. Typical progression is option volume, option price, stock volume, stock price. For those who want to learn more about options, "Options as a Strategic Investment" is an excellent book. I'm wanting to load the boat, but not with the current captain at the helm.
1) look at the spread between Bid and offer in puts, it's huge 2) option volume in the Oct 21 calls is huge. Options signaling a big event is imminent.